Collecting blood samples from cancer patients and healthy donors to study immune cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the feasibility of harvesting and expanding T lymphocytes from both cancer patients and healthy volunteers. It focuses on selecting specific immune cells, particularly PD-1+ and CTLA4+ T cells, from peripheral blood using conjugated antibodies. The study will evaluate the functional anti-tumor cytotoxicity of these selected cells against autologous tumor cells. The research is observational and does not involve any specified interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria for Biospecimen(s) collection:

Cancer Cohort Inclusion Criteria:

1. Male or Female Adult ≥ 18 years of age.
2. Histological diagnosis of any solid tumor type and at any stage of disease progression including in the neoadjuvant/presurgical setting, adjuvant setting, or considered in remission.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (see Appendix 2) and an estimated life expectancy of at least 3 months.
4. Subject or subject's legal representative provides written informed consent.
5. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
6. Additional eligibility criteria need to be met for leukapheresis collection:

   * ECOG Performance Status of 0 or 1 (see Appendix 2)
   * WBC ≥2000/μL
   * Neutrophils ≥1000/μL
   * Platelets ≥100x103/μL
   * Hemoglobin ≥9 g/dL
   * Creatinine ≤2.5 x ULN
   * AST ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases
   * Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg/dL)
   * Negative urine pregnancy test for women of childbearing potential

Healthy Volunteer Cohort Inclusion Criteria:

1. Male or Female Adult ≥ 18 years of age.

   ▪ Pediatric healthy volunteers from 5-17 years of age, with suspected or confirmed COVID-19 diagnosis by laboratory test will be eligible to participate in minimally invasive biospecimen collection procedures, as long as written parental consent has been obtained, and if applicable and technologically able, child assent. Minimally invasive biospecimen collection procedures allowed for pediatric participation include swabs (nasal, NP and OP), microcapillary sampling, and saliva or urine collection.
2. Healthy volunteers are eligible, including the following:

   * History of autoimmune disease or inflammatory disorder considered clinically stable by the Principal Investigator or treating physician's discretion.
   * Suspected or diagnosed COVID-19 disease by laboratory test, whether in the acute, sub-acute or convalesced state.
   * Employees of the study site(s) or BioCytics, as long as fulfilment of inclusion criteria 3.c is obtained.
3. Subject or subject's legal representative provides written informed consent.
4. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, HBV, and HCV.
5. Additional eligibility criteria need to be met for leukapheresis collection:

   * Must be ≥ 18 years of age.
   * WBC ≥2000/μL
   * Neutrophils ≥1000/μL
   * Platelets ≥100x103/μL
   * Hemoglobin ≥9 g/dL
   * Creatinine ≤2.5 x ULN
   * AST ≤2.5 x ULN
   * Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg/dL)
   * Negative urine pregnancy test for women of childbearing potential

2.3.4. Exclusion Criteria

1. Subjects with active infection requiring therapy (fever, localizing source) will be excluded until the infection resolves.

   a. This excludes subjects with suspected or confirmed COVID-19 by laboratory test while in the acute and sub-acute phase of viremia.
2. Underlying medical condition that, in the Principal Investigator's or treating oncologist's opinion, will obscure the interpretation of the patient's safety.
3. Confirmed positive reflex PCR test result for HIV, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV).

Where it's running

• Carolina BioOncology Institute
  Huntersville, North Carolina, United States Recruiting

Study contacts

• Study coordinator: John Powderly, MD
• Phone: 704-947-6599

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer

  This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.

  Recruiting at 4 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07718581

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Personalized PULSAR radiotherapy for advanced small cell lung cancer and brain metastases

  This trial will try personalized PULSAR radiotherapy schedules to see if they are safe and helpful for adults with extensive-stage small cell lung cancer who need thoracic radiation and for adults with 1–5 brain metastases.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07139990

• VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.

  This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.

  Recruiting at 22 sites Phase 1/2 Verastem, Inc. · Los Angeles, California and 21 other locations · NCT07020221

• Using a modified cold virus to treat certain solid tumors

  This study is testing a new treatment made from a modified cold virus to see if it can safely target and help people with certain types of solid tumors.

  Recruiting at 7 sites Phase 1/2 Accession Therapeutics Limited · Barcelona and 7 other locations · NCT06977737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.